Drugs / Amoxicillin-clavulanate
Amoxicillin-clavulanate
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07451171 | Apr → Aug 2026 overdue | small intestinal bacterial overgrowth | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT05664568 | Mar 2023 → Jul 2024 | pulmonary tuberculosis | Western Sydney Local Health District | Unknown | No outcome recorded |
| Phase 2 | NCT04629378 | Aug 2020 → Jun 2021 | tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT07483736 | Mar 2026 → Mar 2028 expected | — | Versailles Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05508152 | Feb 2021 → Jan 2023 | — | Hospital de Granollers | Completed | No outcome recorded |
| Phase 3 | NCT04041791 | Aug 2019 → Apr 2024 | pneumonia | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT01244581 | Sep 1999 → Jun 2012 | suppurative otitis media | University of Oulu | Completed | Met primary |
| Phase 47 trials · 1 met primary | ||||||
| Phase 4 | NCT06494072 | Aug 2024 → May 2028 expected | — | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 4 | NCT06020716 | Aug 2023 → Apr 2028 expected | bronchitis | Helse Stavanger HF | Recruiting | No outcome recorded |
| Phase 4 | NCT05393505 | Oct 2022 → Mar 2025 | neutropenia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT04082598 | Oct 2016 → Sep 2018 | — | Antonio Barone | Completed | No outcome recorded |
| Phase 4 | NCT00377260 | Nov 2006 → Apr 2009 | otitis media | University of Pittsburgh | Completed | Mixed |
| Phase 4 | NCT00368537 | Sep 2006 → Sep 2008 | skin disease caused by bacterial infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00299455 | Mar 2006 → Dec 2008 | otitis media | University of Turku | Unknown | Met primary |
| Phase not applicable4 trials · 1 missed | ||||||
| — | NCT04268407 | Feb 2020 → Dec 2021 | thyroid tumor | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT02740647 | Apr 2016 → Feb 2017 | — | The Baruch Padeh Medical Center, Poriya | Unknown | No outcome recorded |
| — | NCT02567825 | Nov 2015 → Mar 2020 | otitis media | Alejandro Hoberman | Completed | Missed primary |
| — | NCT02724410 | Jan 2011 → Nov 2013 | appendicitis | Wake Forest University Health Sciences | Completed | Mixed |
| Comparator or background therapy19 trials | ||||||
| Phase 0 | NCT04414722 Background | Jan 2021 → May 2023 | diarrheal disease | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT03818815 Comparator | Feb 2019 → Mar 2020 | otitis media | Novus Therapeutics, Inc | Completed | Missed primary |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT01511107 Comparator | Jan 2012 → Sep 2015 | otitis media | Alejandro Hoberman | Terminated | No outcome recorded |
| Phase 2/3 | NCT01530763 Background | Sep 2012 → Apr 2014 | infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT06443502 Background | Nov 2024 → Dec 2029 expected | pouchitis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT04698057 Background | Mar 2022 → Jun 2025 | neutropenia | Poitiers University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT03357614 Comparator | Sep 2018 → Dec 2019 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | Missed primary |
| Phase 3 | NCT03358576 Comparator | Sep 2018 → Oct 2019 | intestinal infectious disease | Iterum Therapeutics, International Limited | Completed | Missed primary |
| Phase 4 | NCT07625267 Comparator | Jul 2026 → Jun 2028 expected | diverticulitis of colon | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT04512638 Background | Jan 2021 → Oct 2025 | osteonecrosis of the jaw | Tim Van den Wyngaert | Unknown | No outcome recorded |
| Phase 4 | NCT04156555 Background | Aug 2019 → Oct 2022 | diarrheal disease | Singapore General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02891915 Comparator | Dec 2016 → Dec 2019 | pneumonia | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT01669980 Background | Oct 2012 → May 2014 | pneumonia | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01111253 Comparator | May 2010 → Apr 2013 | diverticulitis of colon | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT03295955 Comparator | Sep 2017 → Sep 2018 | nodular goiter | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02198001 Comparator | Jan 2014 → Jan 2016 | osteonecrosis of the jaw | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Unknown | No outcome recorded |
| — | NCT01012843 Comparator | Sep 2005 → Jan 2008 | anal fistula | Ankara University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2002-10-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Updated Outlook on 4th Quarter 2002 Earnings in Light of Amox/Clav ANDA Approval tevapharm.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 39 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amoxicillin-clavulanate | “Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after...” NCT02365623 ↗37“Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.” NCT00368537 ↗ “Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.” NCT06443502 ↗ “PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h” NCT01669980 ↗ “Amoxicillin-clavulanate 875mg tid PO” NCT04512638 ↗ |
| Known as | amox/clav | “In the first trial, we compared the efficacy of amoxicillin/clavulanate (amox/clav) administered for 10 days vs. that of placebo” PMID 37171965 ↗ Apr 2023 |
| Known as | amoxicillin-clavulanate potassium | “Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.” NCT00377260 ↗ |
| Known as | Augmentin | “Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with...” NCT00299455 ↗ |
| Known as | Augmentin ES-600 | “Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.” NCT00377260 ↗ |
| Action | Inhibit | “potassium clavulanate, a beta-lactamase inhibitor” NCT02891915 ↗ |
| Modality | Other / unclassified | “oral beta-lactam antibiotic therapy (amoxicillin, amoxicillin-clavulanate, cefdinir)” NCT02891915 ↗ |
| Route | Intravenous | “Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.” NCT00368537 ↗ |